Evidence map›Paper›PMID 40124205›Full record

ArticleClinical case reports2025

Dual Burden of MDR-TB and COVID-19 in a Previously Treated Tuberculosis Case: Diagnostic and Therapeutic Dilemmas.

Gudisa Bereda

Abstract read
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gudisa BeredaPharmacy, All Africa Leprosy Tuberculosis and Rehabilitation Training Centre Addis Ababa Ethiopia.ORCID https://orcid.org/0000-0002-5982-9601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of both MDR-TB and COVID-19 complicates diagnosis and treatment, as their symptoms can overlap, resulting in possible delays in receiving the appropriate care. This study aimed to investigate whether COVID-19 plays a role in the initiation or progression of latent or current tuberculosis (TB) infection, especially MDR-TB, through immunosuppression or lung injury. On May 19, 2022, a retired black African 40-year-old woman was admitted to the emergency room. She had a history of persistent cough, fever, muscle weakness, and weight loss. Reverse transcription polymerase chain reaction (RT-PCR) confirmed the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), indicating a positive COVID-19 diagnosis. GeneXpert MTB/RIF identified

Indexed as

coinfectioncoronavirus disease 2019diagnostic challengesmultidrug‐resistant tuberculosistherapeutic managementtuberculosis

Identifiers

PMID40124205
PMCPMC11925821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.